Ignite Creation Date:
2025-12-25 @ 2:46 AM
Ignite Modification Date:
2025-12-31 @ 1:37 PM
Study NCT ID:
NCT06876233
Status:
RECRUITING
Last Update Posted:
2025-12-12
First Post:
2025-03-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Mobile Cued Adherence Therapy (mCAT) for Blood Pressure Medication
Sponsor:
Chad Stecher@asu.edu
Organization:
Study Overview
Official Title:
Mobile Cued Adherence Therapy (mCAT): A Scalable Habit Formation Intervention to Improve Blood Pressure Medication Adherence Based on a Widely Used Smartphone App
Status:
RECRUITING
Status Verified Date:
2025-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
mCAT
Brief Summary:
The goal of this clinical trial is to determine the effectiveness of a novel mobile health-based habit formation intervention for increasing and maintaining adherence to anti-hypertensive (AH) medication among people living with hypertension and indicate medication nonadherence. The main questions it aims to answer are:
* Can daily incentives for AH pill taking increase and maintain AH medication adherence, control blood pressure, and reduce healthcare utilization and costs?
* Can daily incentives for AH pill taking, combined with action planning (e.g., "After I drink my morning coffee, I will take my medication.") increase and maintain medication adherence, control blood pressure, and reduce healthcare utilization and costs?
* What aspects of daily incentives and/or action planning do participants find most helpful or effective for AH medication adherence?
* What barriers exist for participants who receive daily incentives and/or action planning?
Researchers will compare three study groups: those who only receive daily incentives for the AH pill taking, those who receive daily incentives for AH pill taking combined with action planning, and a control group (who do not receive daily incentives for AH pill taking or action planning). By comparing these three groups, the researchers will be able to determine the effectiveness of the daily incentives with or without action planning for promoting long-term AH medication adherence, reduce healthcare costs, and improve blood pressure.
Participants will:
* Complete 5 online surveys over the course of 2 years (baseline, month 4, month 8, month 12, month 24).
* Submit blood pressure reading for 7 consecutive days after each survey timepoint.
* Submit photo evidence of their AH pill taking for 4 months (intervention groups only).
The highest- and lowest-performing participants in each intervention group will also be invited to complete a 30-minute interview to identify additional factors that contributed to either successful or unsuccessful completion of the intervention.
* Can daily incentives for AH pill taking increase and maintain AH medication adherence, control blood pressure, and reduce healthcare utilization and costs?
* Can daily incentives for AH pill taking, combined with action planning (e.g., "After I drink my morning coffee, I will take my medication.") increase and maintain medication adherence, control blood pressure, and reduce healthcare utilization and costs?
* What aspects of daily incentives and/or action planning do participants find most helpful or effective for AH medication adherence?
* What barriers exist for participants who receive daily incentives and/or action planning?
Researchers will compare three study groups: those who only receive daily incentives for the AH pill taking, those who receive daily incentives for AH pill taking combined with action planning, and a control group (who do not receive daily incentives for AH pill taking or action planning). By comparing these three groups, the researchers will be able to determine the effectiveness of the daily incentives with or without action planning for promoting long-term AH medication adherence, reduce healthcare costs, and improve blood pressure.
Participants will:
* Complete 5 online surveys over the course of 2 years (baseline, month 4, month 8, month 12, month 24).
* Submit blood pressure reading for 7 consecutive days after each survey timepoint.
* Submit photo evidence of their AH pill taking for 4 months (intervention groups only).
The highest- and lowest-performing participants in each intervention group will also be invited to complete a 30-minute interview to identify additional factors that contributed to either successful or unsuccessful completion of the intervention.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| R01HL171706 | NIH | None | https://reporter.nih.gov/quic… | View |